US20050170476A1 - Method for producing phospholipid - Google Patents
Method for producing phospholipid Download PDFInfo
- Publication number
- US20050170476A1 US20050170476A1 US11/065,974 US6597405A US2005170476A1 US 20050170476 A1 US20050170476 A1 US 20050170476A1 US 6597405 A US6597405 A US 6597405A US 2005170476 A1 US2005170476 A1 US 2005170476A1
- Authority
- US
- United States
- Prior art keywords
- phospholipid
- reaction
- phospholipids
- mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 181
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 92
- 238000006243 chemical reaction Methods 0.000 claims abstract description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000004976 Lyotropic liquid crystal Substances 0.000 claims abstract description 32
- 239000002994 raw material Substances 0.000 claims abstract description 29
- 239000003960 organic solvent Substances 0.000 claims abstract description 28
- 108090000553 Phospholipase D Proteins 0.000 claims abstract description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 102000011420 Phospholipase D Human genes 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 56
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 39
- 229960001153 serine Drugs 0.000 claims description 35
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 32
- 235000002639 sodium chloride Nutrition 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 238000000265 homogenisation Methods 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 11
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 11
- 239000008157 edible vegetable oil Substances 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- 229960001031 glucose Drugs 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 229910003002 lithium salt Inorganic materials 0.000 claims description 3
- 159000000002 lithium salts Chemical class 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 20
- 239000011575 calcium Substances 0.000 abstract description 20
- 229910052791 calcium Inorganic materials 0.000 abstract description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- 239000002244 precipitate Substances 0.000 description 31
- 150000008106 phosphatidylserines Chemical class 0.000 description 29
- 239000000370 acceptor Substances 0.000 description 28
- 239000007864 aqueous solution Substances 0.000 description 24
- 238000005191 phase separation Methods 0.000 description 24
- 239000007795 chemical reaction product Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 20
- 229960005069 calcium Drugs 0.000 description 19
- 238000004549 pulsed laser deposition Methods 0.000 description 16
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 239000000758 substrate Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000001110 calcium chloride Substances 0.000 description 11
- 229910001628 calcium chloride Inorganic materials 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000002051 biphasic effect Effects 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 239000004973 liquid crystal related substance Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 229940083466 soybean lecithin Drugs 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- -1 phosphatidyl ascorbate Chemical compound 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000019485 Safflower oil Nutrition 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000014121 butter Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 235000014593 oils and fats Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 235000020138 yakult Nutrition 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 3
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 240000006474 Theobroma bicolor Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000003012 bilayer membrane Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- SFGGITYAMFZATC-UHFFFAOYSA-N ClC(Cl)Cl.CC(C)CC(C)(C)C Chemical compound ClC(Cl)Cl.CC(C)CC(C)(C)C SFGGITYAMFZATC-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- NPAGFLVMYDKFJH-UHFFFAOYSA-N dichloromethane;2,2,4-trimethylpentane Chemical compound ClCCl.CC(C)CC(C)(C)C NPAGFLVMYDKFJH-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000010459 dolomite Substances 0.000 description 1
- 229910000514 dolomite Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000021546 granular confectionery Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000010461 other edible oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6481—Phosphoglycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
Definitions
- the present invention relates to a method for producing an objective phospholipid using transphosphatidylation (phospholipid base exchange reactions).
- Phospholipids such as phosphatidylserines (PSs) and phosphatidylglycerols (PGs) each have their useful physiological or biological functions and specific physical properties and are used in, for example, pharmaceutical preparations, food materials, and emulsifying agents.
- PSs phosphatidylserines
- PGs phosphatidylglycerols
- phosphatidylserines are promising as drugs for prophylaxis and/or therapy of senile dementia and dysmnesia (memory disorder)
- phosphatidylglycerols are promising as emulsifying agents
- phosphatidylascorbic acids are promising as emulsifying agents and lipoperoxides inhibitors.
- phospholipids have been conventionally produced by chemical synthesis or by transphosphatidylation using phospholipase D.
- enzymatic methods can relatively easily produce phospholipids at relatively low cost and are widely used.
- Japanese Patent No. 2,942,302 describes a homogenous reaction in which a phospholipid preparation containing about 85% of phosphatidylcholine prepared by fractionating soybean lecithin is dissolved in ethyl acetate, the resulting solution is mixed with an ascorbic acid aqueous solution to yield a mixture, and the mixture is allowed to react with phospholipase D to thereby yield a reaction product containing phosphatidyl ascorbate.
- the biphasic reaction must be carried out in the presence of solvents (an organic solvent and water) five times or more (volume/weight) as much as the phospholipid and thereby must use a reactor having a volume capacity six times as much as the amount of the phospholipid.
- solvents an organic solvent and water
- calcium added to accelerate the reaction rapidly forms a salt with the phospholipid.
- the formed calcium salt is belonging to the category of chemically synthesized substances in Japan and Europe, and the product is thereby difficult to use in food.
- the reaction system contains large amounts of water and yields a phosphatidic acid, as a by-product, due to hydrolytic activity of phospholipase D during a continuous reaction, thus the separation and purification of the objective phospholipid becoming difficult.
- the proportion of the acceptor to the phospholipids is limited in the homogenous reaction, and thereby the production amount of the objective reaction product (phospholipid) is limited.
- JP-B-7-016426 describes that phosphatidylserine, phosphatidylglycerol, and others are produced by a reverse micelle reaction in which an aqueous phase containing calcium chloride, a hydroxyl-containing acceptor, and phospholipase D and being encapsulated in a reversed micelle is allowed to react with a solution of a raw material phospholipid in an organic solvent (diisopropyl ether, isooctane, cyclohexane, benzene, chloroform-isooctane, n-hexane, or dichloromethane-isooctane).
- an organic solvent diisopropyl ether, isooctane, cyclohexane, benzene, chloroform-isooctane, n-hexane, or dichloromethane-isooctane.
- an object of the present invention is to provide a method for producing phospholipid by transphosphatidylation, using phospholipase D, which can easily produce the objective phospholipid in a high yield without using organic solvents and/or calcium.
- the above object can be achieved by a method for producing phospholipid through transphosphatidylation, comprising the steps of homogenizing a mixture of a raw material phospholipid, a hydroxyl-containing acceptor (accepter having one or more hydroxyl groups), phospholipase D, and water in the absence of an organic solvent to obtain a homogenized mixture; and subjecting the homogenized mixture to a transphosphatidylation reaction at a temperature within a range from 15° C. to 65° C.
- the four components, the raw material phospholipid, the hydroxyl-containing acceptor, phospholipase D, and water, are sufficiently mixed, and the resulting mixture is further homogenized.
- the homogenized mixture is supposed to have a lamellar lyotropic liquid crystal structure.
- the term “lamellar lyotropic liquid crystal” means a liquid crystal of a phospholipid bilayer membrane formed by adding water to a phospholipid.
- the homogenized mixture has an array structure containing the bilayer membrane (sometime a polymolecular layer membrane structure) and an aqueous layer alternately continuously arrayed.
- the lamellar lyotropic liquid crystal structure can be identified by, for example, microscopic observation of the homogenized mixture under crossed Nicols.
- a “lamellar lyotropic liquid crystal structure substantially without phase separation” mentioned later and a “lamellar lyotropic liquid crystal structure with phase separation” are observed as a continuous lamellar structure and as a closed-ring structure floated in an aqueous phase, respectively.
- the lamellar lyotropic liquid crystal structure is generated in the following manner. That is, by adding water to the raw material phospholipid in the homogenization procedure, the interaction between hydrophilic groups in the phospholipid becomes weak, and its crystal structure disintegrates to forme a lamellar liquid crystal. Because of the formation of the lamellar lyotropic liquid crystal structure, water can freely move between layers of the lamellar structure of the phospholipid to make it efficient to supply the acceptor and/or the enzyme and to remove polar heads liberated from the phospholipid, thereby enabling a transphosphatidylation reaction.
- the entire homogenized mixture must have the lamellar lyotropic liquid crystal structure.
- the individual components must be homogenized in addition to simply mixed.
- the entire homogenized mixture preferably has the lamellar lyotropic liquid crystal structure (i.e., the mixture substantially has the lamellar lyotropic liquid crystal structure) as a result of homogenization for a higher yield of the reaction product.
- a water content in the homogenized mixture affects the formation of the lamellar lyotropic liquid crystal structure. If the water content is within a specific range (e.g., from about 10 wt % to about 100 wt % relative to the amount of soybean phospholipid), the homogenized mixture will have a lamellar (neat) liquid crystal with substantially no phase separation. However, if the water content is excessively higher than the specific range, the homogenized mixture may undergo phase separation to form two phases containing a liquid and a liquid crystal.
- a specific range e.g., from about 10 wt % to about 100 wt % relative to the amount of soybean phospholipid
- the reaction is preferably performed while the homogenized mixture is without phase separation or with substantially no phase separation (hereinafter both are referred to as “lamellar lyotropic liquid crystal structure substantially without phase separation”) for a further higher transfer activity.
- the liquid crystal may constitute discontinuous small granules floating in the solvent. Accordingly, the contact efficiency between water and the phospholipid decreases, thus decreasing transfer activity as compared with the case without phase separation. If the water content is excessively low, the phospholipid may maintain its crystal structure to inhibit the formation of a lamellar lyotropic liquid crystal structure overall the phospholipid to thereby lose the field of an enzymatic reaction. Alternatively, the homogenized mixture may have decreased fluidity and thereby have a deteriorated contact efficiency between the substrate and the enzyme, thus the enzyme cannot efficiently act upon the substrate.
- Organic solvents are preferably not used in the homogenization procedure. If an organic solvent is added during the homogenization procedure, phase separation as in conventional biphasic reactions (not phase separation in the lamellar lyotropic liquid crystal structure but separation between an oil phase and an aqueous phase) may be enhanced. In addition, the addition of an organic solvent invites various disadvantages as described above.
- Raw material phospholipids for use in the present invention include any of phospholipid-containing natural products, extracts or purified extracts of such natural products, and synthetic phospholipids.
- the phospholipids include, but are not limited to, soybean lecithin, rapeseed lecithin, egg yolk lecithin, corn lecithin, cottonseed lecithin, purified products of these lecithins; phosphatidylcholines (hereinafter briefly referred to “PC(s)”), phosphatidylethanolamines (hereinafter briefly referred to as “PE(s)”), and mixtures of these substances.
- PC(s) phosphatidylcholines
- PE(s) phosphatidylethanolamines
- soybean lecithin, rapeseed lecithin, egg yolk lecithin, and purified products of these lecithins are preferred for their availability and cost
- Hydroxyl-containing acceptors for use in the present invention are not specifically limited as long as they can receive or accept a phosphatidyl group of the raw material phospholipid in the presence of phospholipase D.
- Such hydroxyl-containing acceptors include, for example, serine, glycerol, L-ascorbic acid, glucose, choline, ethanolamine, 1-amino-2-propanol, and 1-o-methyl-glycoside.
- serine, choline, L-ascorbic acid, glucose, and glycerol are preferred for a higher yield of the objective product, of which serine and glycerol are typically preferred.
- Phospholipase Ds for use herein are not specifically limited as long as they have ransphosphatidylation activity and include, for example, free or chemically modified PLDs, and immobilized enzymes immobilized to a carrier such as ion exchange resins and silica gel. Among them, free PLDs are preferred for a further higher yield of the reaction product.
- any of PLDs derived from plants or vegetables such as cabbage and carrot PLDs derived from microorganisms such as mycobacteria, bacteria, yeasts, and fungi (molds), and PLDs derived from animals can be advantageously used. They may be prepared products prepared according to a conventional procedure or commercially available products such as a cabbage-derived PLD (e.g., Product Number P 7758, Sigma Chemical Company), peanut-derived PLD (e.g., Product Number P 0515, Sigma Chemical Company), and a PLD derived from Streptmyces chromofuscus.
- a cabbage-derived PLD e.g., Product Number P 7758, Sigma Chemical Company
- peanut-derived PLD e.g., Product Number P 0515, Sigma Chemical Company
- PLD derived from Streptmyces chromofuscus e.g., Streptmyces chromofuscus.
- the raw material phospholipid, the hydroxyl-containing acceptor, PLD, and water are initially mixed, and the resulting mixture is further subjected to a homogenization procedure.
- the homogenization procedure herein means homogenous dispersion of the four components in the mixture by the application of physical force by means of, for example, physical agitation, ultrasonic treatment, etc. More specifically, homogenization treatments using a Vibromixer, automatic mortar, Homo Mixer, Physcotron, food processor, or sonicator alone or in combination can be employed. If the amount of the mixture is small, it may be kneaded using, for example, a microspatula.
- the four components may be mixed and homogenized separately in time or simultaneously. For example, one of the four components may be mixed and homogenized with another, and this procedure is repeated. It is also acceptable that two, three or four of the components are mixed or dissolved in advance, and then the resulting mixture or solution is ultimately homogenized.
- the yield of the objective phospholipid significantly decreases. This is probably for the following reasons. That is, the raw material phospholipid is generally a hard paste at room temperature, and the entire mixture cannot have a lamellar lyotropic liquid crystal structure by simply mixing the other components. As a result, the individual components come in contact with one another at a lower frequency to thereby decrease the yield of the objective product. Accordingly, the mixture of the components must be applied with physical force to such an extent as to disperse the individual components and must be subjected to a “homogenization procedure”.
- the hydroxyl-containing acceptor can be used as an aqueous solution or as a powder in the homogenization procedure.
- PLD is used as a solution in a small amount of water or as a powder.
- phosphatidic acid hereinafter referred to as “PA”
- PA phosphatidic acid
- the amount of water content in the homogenization procedure affects the phase separation of the lamellar lyotropic liquid crystal structure and the yield of the reaction product phospholipid and is preferably controlled and adjusted to prevent the phase separation.
- the water content in the lamellar lyotropic liquid crystal structure is preferably from 10 wt % to 100 wt % and more preferably from 20 wt % to 60 wt % relative to the amount of the raw material phospholipid to substantially prevent the phase separation.
- water content in the lamellar lyotropic liquid crystal structure means the amount of water in the homogenized mixture after removing water separated during the homogenization procedure and can be determined by, for example, a conventional Karl Fischer technique.
- the separated water may be removed by decantation or centrifugal separation, for example, at 150 g for about 1 minute.
- the amount is preferably from about 0.3 mole to about 10 moles and more preferably from about 4 moles to about 8 moles per 1 mole of the raw material phospholipid. If an excessively large amount (exceeding 10 moles) of the acceptor is added, the recovery of an unreacted acceptor may require increased efforts. In contrast, if the amount is excessively small, the yield of the objective product may decrease.
- the amount of serine as the hydroxyl-containing acceptor is preferably from 5 wt % to 150 wt %, and more preferably from 50 wt % to 100 wt % relative to the amount of the raw material phospholipid.
- the amount of glycerol as the hydroxyl-containing acceptor is preferably from 10 wt % to 200 wt %, and more preferably from 20 wt % to 100 wt %.
- the amount of PLD is not specifically limited, can be determined depending on, for example, the reaction time in the subsequent reaction step and is generally from about 500 to 100,000 units per kg of the phospholipid.
- a temperature in the homogenization procedure is not specifically limited and is preferably from about 15° C. to 65° C. If the temperature is lower than 15° C., it may require extra energy to cool the reaction system, and the mixture may not sufficiently be homogenized. If it is higher than 65° C., the phospholipid may become unstable.
- an edible oil and/or fat can be added during the homogenization procedure within ranges not deteriorating the lamellar lyotropic liquid crystal structure.
- an edible oil and/or fat enhances the conversion of the lamellar lyotropic liquid crystal structure into a biphasic system as organic solvents, a small amount of the edible oil and/or fat increases the fluidity of the homogenized mixture to thereby increase the yield of the objective phospholipid.
- Such edible oils and fats include, but are not limited to, safflower oil, soybean oil, corn oil, rapeseed oil, cottonseed oil, sunflower oil, safflower oil, sesame oil, olive oil, hempseed oil, perilla oil, theobroma oil (cacao butter), coconut oil, and other vegetable oils; butter oil, fish oil, lard, beef tallow, and other animal oils; and middle-chain triacylglycerols (MCTs).
- MCTs middle-chain triacylglycerols
- the amount of the edible oil and/or fat is preferably less than or equal to an equivalent amount and more preferably from 5 wt % to 15 wt % relative to the amount of the raw material phospholipid.
- the homogenous phase reactions require a solvent two times (volume/weight) or more as much as the phospholipid and thereby require a reactor having a capacity three times (volume/weight) or more as much as the phospholipid.
- the amount of the acceptor is limited to maintain their homogenous phase, and it is difficult to obtained a reaction product containing the objective compound in a high content.
- the amount of serine that can be added to 1 kg of the phospholipid is 0.15 kg and the PS content in the reaction products phospholipids is at most 35%.
- the method of the present invention can reduce the capacity of a reactor to produce an equivalent amount of the objective phospholipid and can yield reaction products containing the objective compound in a high content as compared with the homogenous reactions.
- each of the conventional transphosphatidylation reactions must be performed in the presence of an organic solvent such as an ether, toluene, n-hexane, or ethyl acetate in their reaction system.
- an organic solvent such as an ether, toluene, n-hexane, or ethyl acetate in their reaction system.
- the method according to the present invention does not require organic solvents and is therefore advantageous in the production of the phospholipids for food and other substances in which the use of organic solvents is restricted.
- the reaction proceeds even without the addition of calcium ions in contrast to the conventional methods. While not being clarified, this is probably because the reaction is performed in a liquid crystal according to the present invention and thereby the raw material phospholipid becomes structurally susceptible to transphosphatidylation reactions regardless of the presence or absence of calcium ion.
- the conventional biphasic reaction is performed in a liquid.
- the homogenized mixture thus obtained is subjected to a transphosphatidylation reaction in the absence of an organic solvent to yield the objective phospholipid.
- the reaction is performed at a temperature preferably within a range from 15° C. to 65° C. and more preferably from 45° C. to 55° C. If the reaction temperature is lower than 15° C., the reaction may not be enhanced to proceed to thereby deteriorate the yield of the objective phospholipid. If the reaction temperature is higher than 65° C., side reactions of phospholipid, such as decomposition and/or oxidation of the produced phosphatidylserine, may occur.
- a reaction time is not specifically limited, can be appropriately selected depending on the reaction temperature, the types and amounts of the components and is preferably from about 1 to 48 hours for a better yield of the objective phospholipid and less by-production of PA.
- the transphosphatidylation reaction can be performed left stand or with stirring.
- the reaction can be performed with stirring using a tabletop universal mixer (e.g., KINMIX MAJOR (trademark), Type-KM-230).
- a lamellar liquid crystal structure without phase separation is formed entirely in the homogenized mixture by mixing an appropriate amount of water with the raw material phospholipid, and water can freely move between layers of the lamellar structure of the phospholipid, thereby efficiently supplying the hydroxyl-containing acceptor and/or the enzyme as well as efficiently removing polar heads liberated from the phospholipid. Accordingly, it is possible to achieve the transphosphatidylation reaction at high activity, and the objective phospholipid can be easily obtained in high yield at low cost.
- Phospholipids obtained according to the present invention may contain impurities derived from the raw material phospholipid and the acceptor, and other substances in addition to by-product PA.
- the obtained phospholipid is therefore often a phospholipid mixture containing the objective phospholipid, other phospholipids and impurities.
- the phospholipid obtained by the transphosphatidylation is preferably used after the removal of such impurities by subjecting the same to an appropriate purification process but can be used while containing impurities derived from the raw materials or formed in the production processes as long as the impurities do not invite problems in administration or deteriorate the advantages.
- the product can be purified by any technique such as fractionation using a solvent and chromatography in appropriate combination according to a conventional procedure.
- the phospholipids obtained according to the present invention can be administered in the form of, for example, pharmaceutical preparations, food, or cosmetics.
- pharmaceutical preparations for example, to be used in the form of pharmaceutical preparations to utilize the biological functions of the phospholipids, they can be orally administered in the dosage form of, for example, capsules, granules, tablets, powders, and other solid preparations; and syrups, and other liquid preparations.
- they can be administered in the form of, for example, injections, dermatologic external preparations, rectal infusions, and other non-oral preparations.
- additional pharmaceutically acceptable components can be used according to necessity.
- Such components include, for example, lactose, starches, crystalline cellulose, calcium lactate, magnesium aluminometasilicate, silicic anhydride, and other excipients; sucrose, hydroxypropylcellulose, polyvinylpyrrolidone, and other binders; carboxymethylcellulose, carboxymethylcellulose calcium, and other disintegrators; magnesium stearate, talc, and other lubricants.
- the phospholipid obtained according to the method of the present invention is used in food in the expectation of similar biological functions, such food can be appropriately produced according to a conventional procedure by adding the phospholipid as intact or after purification to oils and fats, tablet or granular confectionery, fermented milk, candies, spices, fish and vegetables flakes to sprinkle on cooked rice, and other food and drinks.
- an appropriate amount of the phospholipids obtained by the method of the present invention can be used in the form of these pharmaceutical preparations and food.
- the amount thereof may be such as to yield the functions and not to invite problems such as overdose.
- the compositional amount of phosphatidylserine produced as the phospholipid is such an amount as to take in from about 50 mg to 1,000 mg a day.
- the phospholipids obtained by the method according to the present invention can also be used as emulsifying agents.
- the emulsifying agent may be added to, for example, pharmaceutical preparations, food, and cosmetics in an amount preferably from 0.01% to 10%.
- a phosphatidylserine can be easily purified and concentrated from a phospholipid mixture containing the phosphatidylserines by dissolving the phospholipid mixture in an alcohol to yield a solution, adding a metallic salt to the solution to insolubilize the phosphatidylserines, and separating the insolubilized matter.
- Such metallic salts for use herein include, but are not limited to, lithium salts, sodium salts, potassium salts, calcium salts, magnesium salts, and other metallic salts, as well as natural products containing any of these metallic salts in abundance, such as common salt, bittem, brine, dolomite, and edible powdery mother of pearl.
- lithium salts, sodium salts, and potassium salts are preferred for efficient concentration, of which lithium chloride, sodium chloride, and potassium chloride are typically preferred.
- Each of these metallic salts can be used alone or in combination.
- the amount of the metallic salt(s) is not specifically limited as long as phosphatidylserine can be precipitated and is preferably from 0.15 to 10 mmol, and more preferably from 0.5 to 5 mmol per gram of the phospholipid for a higher recovery rate of the phosphatidylserines and a higher content of the phosphatidylserines in the precipitate.
- Any alcohol can be used herein as long as it can dissolve the phospholipid mixture, of which methyl alcohol, ethyl alcohol, butyl alcohol, propyl alcohol, isopropyl alcohol, and other lower alcohols are preferred. Mixtures of these alcohols can also be used. Ethyl alcohol can be easily applied to food with less problems in safety and is typically advantageously used.
- the concentration of the phospholipid mixture in the alcohol is not specifically limited, is preferably equal to or more than such a concentration that the mixture can be completely dissolved in the alcohol and is preferably from 1 to 50%, and more preferably from 2 to 20% relative to the weight of the alcohol for efficient concentration procedure of the phosphatidylserines and for higher operability.
- the phosphatidylserines can be concentrated from the phospholipid mixture, for example, in the following manner. Initially, the phospholipid mixture prepared by transphosphatidylation and containing other phospholipids in addition to the phosphatidylserines is dissolved in an alcohol such as ethyl alcohol. In this procedure, dissolution conditions such as dissolution temperature are not specifically limited and can be appropriately selected depending on the types and amounts of components of the mixture and other parameters.
- the phosphatidylserines, PC, PA, and other phospholipids are extracted into a solvent layer, but some insoluble matters may form. Accordingly, the metallic salt is added after removing such precipitates, aggregates, and other insoluble matters from the solvent by means of, for example, centrifugal separation and/or filtration. If the insoluble matters include a small amount of phosphatidylserine, extraction operation with the alcohol can be repeated several times.
- the metal salt is added to the alcohol solution to thereby fractionate the phosphatidylserines extracted in the solvent layer. Specifically, most of the other phospholipids than the phosphatidylserines in the solvent layer do not precipitate by the addition of the metal salt, but most of the phosphatidylserines precipitates, and thus the phosphatidylserines can be concentrated by recovering the precipitated phosphatidylserine.
- the metal salt can be added as a powder or a solution in a solvent such as water or an alcohol. Conditions in the procedure are not specifically limited and can be appropriately selected depending on, for example, the types and amounts of components of the mixture. More specifically, the mixture with the metallic salt is held at 10° C. to 30° C. for 30 minutes or longer to thereby insolubilize PS.
- the phosphatidylserines insolubilized as a result of addition of the metallic salt can be recovered by a means such as centrifugal separation, filtration, and standing separation.
- the phosphatidylserines can be further purified by a conventional purification means such as column chromatography.
- the phosphatidylserines concentrate according to the present invention contains significantly reduced amounts of other phospholipids and other components and can thereby be relatively easily purified.
- FIG. 1 is a diagram of test results on optimum amounts of MCT with the ordinate A showing the PS production rate (%) and the abscissa B showing the added amount ratio (%) of MCT to the phospholipids.
- FIG. 2 is a diagram of test results on optimum amounts of MCT with the ordinate C showing the ratio (%) of MCT to the phospholipids and the abscissa D showing the PS production rate (%).
- FIG. 3 is a diagram of test results on molar ratios of serine to phospholipids in a homogenized mixture with the ordinate E showing the PS production rate (%) and the abscissa F showing the molar ratio (mol/mol) of serine to the phospholipids.
- FIG. 4 is a diagram of test results on weight ratios of water to phospholipids in a homogenized mixture with the ordinate G showing the PS production rate (%) and the abscissa H showing the ratio (% by weight) of water to the phospholipids.
- FIG. 5 is a diagram of test results on weight ratios of water to phospholipids in a homogenized mixture with the ordinate I showing the PS production rate (%) and the abscissa J showing the ratio (% by weight) of water to the phospholipids.
- FIG. 6 is a diagram of test results on weight ratios of water to phospholipids in a homogenized mixture with the ordinate K showing the PS production rate (%) and the abscissa L showing the ratio (% by weight) of water to the phospholipids.
- FIG. 7 is a diagram showing production rates of PS at different reaction temperatures with the ordinate M showing the PS production rate (%) and the abscissa N showing the temperature (°C.).
- a total amount of 97 g of 6.7 M L-serine aqueous solution (with or without 0.18 M calcium chloride) was kneaded (homogenized) with 100 g of a mixture of soybean lecithin and cocoa butter (NATHIN 250, trademark, available from Central Soya Company, Inc.) in an automatic mortar (Model ANM-150) and was held at 55° C.
- a total of amount 2.0 mL of an enzyme mixture containing 800 units of phospholipase D-Y1 derived from an actinomycete belonging to Streptomyces (PLD-Y1, product name, available from Yakult Honsha Co., Ltd.) was kneaded (homogenized) with the kneaded mixture in an automatic mortar, and a reaction was performed in the absence of organic solvents.
- the transphosphatidylation reaction was performed with stirring at 55° C. for 17 hours and was complete.
- the present invention provides a method for performing a transphosphatidylation reaction without the use of organic solvents. Specifically, transphosphatidylated products can be efficiently produced by homogenizing an aqueous solution containing the hydroxyl-containing acceptor and phospholipase D with the phospholipid before reaction.
- the method does not require any organic solvent.
- an oil-soluble substance other than organic solvents can be added to the phospholipid to thereby further improve the operability.
- oil-soluble substances include, but are not limited to, safflower oil, soybean oil, corn oil, rapeseed oil, cottonseed oil, sunflower oil, safflower oil, sesame oil, olive oil, hempseed oil, perilla oil, theobroma oil (cacao butter), coconut oil, and other vegetable oils; butter oil, fish oil, lard, beef tallow, and other animal oils; MCTs as glyceride derivatives prepared from middle-chain fatty acids as starting materials; and other edible oils and fats.
- Example 1 show that the transphosphatidylation reaction proceeds even without the addition of calcium.
- the effects of the addition of calcium were further investigated. Specifically, individual components were mixed with or without the addition of calcium as shown in Table 1 while the molar ratio of serine to the phospholipid was set at 1 or 5. The resulting mixture was kneaded (homogenized) using a microspatula and was allowed to react at 55° C. for 18 hours. In this procedure, a sample with the molar ratio of 1 employed 2.5 M serine aqueous solution, and one with the molar ratio of 5 employed 4.5 M serine aqueous solution. More specifically, NATHIN 250 and the serine aqueous solution containing, if any, calcium were mixed, and the resulting mixture was treated with the PLD-Y1 aqueous solution to initiate a reaction.
- NATHIN 250 available from Central Soya Company, Inc.
- 500 mL of a reagent chemical acetone by heating to 60° C.
- the solution was cooled to 15° C.
- the resulting precipitate was dissolved in 300 mL of a reagent chemical acetone by heating to 60° C., the solution was then cooled to 15° C. and thereby yielded a precipitate comprising phospholipids alone with no triglyceride.
- NATHIN 250/acetone precipitate a dried product of the precipitate (hereinafter referred to “NATHIN 250/acetone precipitate”) was kneaded (homogenized) with 5.8 g of 4.5M L-serine aqueous solution (with or without the addition of 0.18 M calcium chloride), and the kneaded article was held at 55° C.
- the kneaded article was further kneaded (homogenized) with 0.2 mL of an enzyme mixture containing 49.3 units of Phospholipase D Y-1 (available from Yakult Honsha Co., Ltd.) using a microspatula, and the kneaded article was immediately subjected to a reaction at 55° C.
- Raw material phospholipids were prepared by kneading 1 to 9% by weight of MCT (Panasate 810, trademark, available from Nippon Oil And Fats Co., Ltd.) into NATHIN 250/acetone precipitate. Each of the material phospholipids was further kneaded with 200 mg of serine and 200 mL of water (molar ratio of phospholipids to water 0.4) relative to 500 mg of NATHIN 250/acetone precipitate. The kneaded article was further kneaded (homogenized) with a PLD-Y1 aqueous solution (4.1 units per 15 mL) using a microspatula and was allowed to react at 55° C. for 17 hours. Phosphatidylserines after the completion of reaction were determined by silica gel thin-layer chromatography.
- FIG. 1 is a diagram showing test results on optimum amounts of MCT.
- the PS production rate increases from 34.7% to 40.4% as compared with the case where MCT is not added, verifying effects of the addition of MCT. Reactions were performed in the same manner with a varying ratio of MCT of 10% to 40%.
- FIG. 2 is a diagram showing test results on optimum amounts of MCT. As shown in FIG. 2 , the PS production rate increases in all the samples with 10% to 40% of MCT. Apparently. FIGS. 1 and 2 indicate that the amount of MCT is preferably from 9% to 40%. Homogenized mixtures before the initiation of the reaction were observed with a microscope under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation”.
- NATHIN 250 To 500 mg of NATHIN 250 was added 2.5 M serine aqueous solution containing 0.18 M calcium chloride in a varying molar ratio of serine to phospholipids from 0.1 to 15, and the mixture was mixed in a mixer while warming on a water bath at 60° C. After cooling the water bath to 55° C., the reaction substrate was further mixed and homogenized with a PLD-Y1 aqueous solution using a microspatula or Vibromixer. The homogenized mixture was allowed to react at 55° C. for 17 hours, and the phospholipid composition of reaction products was analyzed by silica gel thin-layer chromatography.
- FIG. 3 shows that the PS content in the reaction products is 20% or more at molar ratios of serine to phospholipids of 0.3 or more, indicating that these are suitable conditions for the production of PS.
- molar ratios of 4 or more can achieve PS contents of 45% or more and are typically preferred as substrate compositions.
- the production of PS does not increase with an increasing amount of serine, indicating that an upper limit of the molar ratio for efficient production of phosphatidylserines is about 10.
- Homogenized mixtures at molar ratios from 0.3 to 10) before reaction were subjected to microscopic observation under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation”.
- the amount of water relative to phospholipids was 100 parts by weight or more at molar ratios of serine of 6 or more. However, the amount of water in the homogenized mixtures as determined by the Karl Fischer's technique was 100 parts by weight or less after removal of separated water by decantation.
- a total amount of 200 mg each of powdery L-serine was sufficiently mixed with 500 mg of soybean lecithin (NATHIN 250/acetone precipitate, or PC 80 available from Croklaan B. V.) or egg yolk lecithin (PL-100LE, available from Q.P. Corporation) in a mortar heated at 60° C.
- the mixture was further kneaded with distilled water in water contents shown in FIGS. 4 to 6 and was held at 55° C.
- a total of 0.015 mL of an enzyme mixture containing 4.1 units of PLD-Y1 (available from Yakult Honsha Co., Ltd.) was kneaded (homogenized) with the kneaded article using a microspatula, and a transphosphatidylation reaction was performed at 55° C. for 17 hours while left stand and was complete.
- the water contents in the homogenized mixtures were determined by the Karl Fischer's technique.
- FIGS. 4 to 6 are diagrams of results with the ordinate showing PS contents (%) in the reaction products and the abscissa (logarithmically plotted) showing the ratio (% by weight) of water to soybean lecithin.
- FIG. 4 shows that when NATHIN 250/acetone precipitate was used as a raw material phospholipid, PS was not produced at a weight ratio of water to the phospholipids in the homogenized mixture of 3%, but 10% or more of the phospholipid was converted into PS at weight ratios from 10% to 100%, indicating that these weight ratios are suitable for the production of PS. A total of 30% or more of the phospholipid was converted into PS at weight ratios of water to the phospholipids from 20% to 70%, indicating that these weight ratios are optimum for the production of PS.
- FIG. 5 shows that when PC 80 was used as a raw material phospholipid, PS was not produced at a weight ratio of water to the phospholipids in the homogenized mixture of 8%, but 10% or more of the phospholipid was converted into PS at weight ratios from 10% to 60%, indicating that these weight ratios are suitable for the production of PS. A total of 20% or more of the phospholipid was converted into PS at weight ratios of water to the phospholipids from 20% to 40%, indicating that these weight ratios are optimum for the production of PS.
- FIG. 6 shows that when the egg yolk lecithin was used as a raw material phospholipid, PS was not produced at a weight ratio of water to the phospholipids in the homogenized mixture of 8%, but 10% or more of the phospholipid was converted into PS at weight ratios from 15% to 40%, indicating that these weight ratios are suitable for the production of PS. A total of 20% or more of the phospholipid was converted into PS at weight ratios of water to the phospholipids from 20% to 35%, indicating that these weight ratios are optimum for the production of PS.
- aqueous solutions of acceptors indicated in Table 5 were mixed with 500 mg of PC 80 on a water bath at 60° C., the mixture was kneaded (homogenized) with 50 mL of an aqueous solution containing 13.7 units of a PLD (PLD-Y1) using a microspatula, and the kneaded article was allowed to react at 55° C. for 18 hours. Transphosphatidylation reaction products were analyzed by silica gel thin-layer chromatography.
- Table 5 shows production rates of transferred products after transfer reactions using each of the acceptors.
- Table 5 demonstrates that corresponding transphosphatidylated products (phosphatidylglycerol: 42.7%, phosphatidylascorbic acid: 9.4%, phosphatidylglucose: 13.3%) were produced when glycerol, L-ascorbic acid, and glucose were each used as the acceptor.
- no transphosphatidylated product was produced when inositol, ascorbate phosphates, and trehalose were used.
- a total of 490 mg each of 4.5 M serine aqueous solution was added to 500 mg of NATHIN 250/acetone precipitate (PL) or of a phospholipid substrate (PL+TG) comprising 450 mg of NATHIN 250/acetone precipitate and 50 mg of MCT, the resulting mixture was kneaded at 60° C., was further kneaded (homogenized) with 15 mL of an aqueous solution containing 4.1 units of PLD-Y1 using a microspatula and was allowed to react at temperatures from 15° C. to 65° C. in increments of 10° C. for 18 hours. Transphosphatidylated products were analyzed by silica gel thin-layer chromatography.
- FIG. 7 is a diagram showing production rates of PS at different reaction temperatures and shows that the production rate of PS at 45° C. was 43% and did not change with an elevating temperature when the substrate containing NATHIN 250/acetone precipitate and MCT was used.
- a total of 490 mg of 4.5 M serine aqueous solution (containing, if any, 9.3 mg of calcium) was mixed with 500 mg of NATHIN 250 at 55° C. After cooling to 45° C., the reaction mixture was treated with 200 mL of a liquid enzyme mixture (0.6 units per milliliter) of Brussels sprout PLD at 45° C. for 18 hours.
- the Brussels sprout PLD had been separately prepared according to a conventional procedure.
- soybean lecithin containing 40% of PC were kneaded 190 g of a serine aqueous solution containing 70 g of serine in 120 g of water and 10 mL of an aqueous solution (24 mg/mL) of phospholipase D (PLD-Y1, available from Yakult Honsha Co., Ltd.).
- the kneaded article was allowed to react at 55° C. for 5 hours and thereby yielded a reaction product containing 46.7% of PS in phospholipids.
- a total of 5.0 g of the reaction product was extracted with 20 mL of ethyl alcohol at 45° C., and the residue (precipitate) was further extracted with two portions of 5 mL of ethyl alcohol.
- Three extracts were mixed, 5 mL of which was treated with 0.20 mL of 25% common salt (sodium chloride) aqueous solution, was heated to 45° C., was left stand at room temperature and thereby yielded a precipitate.
- the precipitate contained 62.1% of PS on dried solid matter basis, whereas a supernatant contained 3.3% of PS, indicating that PS was efficiently concentrated in the precipitated.
- Example 10 A 25% common salt aqueous solution was added to the mixture of the extracts obtained in Example 10 and thereby yielded insolubilized PSs.
- the amounts of PSs in the precipitated phospholipids and in the recovered precipitate were determined.
- Table 6 shows the relationship among the amount of common salt, the recovery rate of PS in the precipitate and the PS content in the phospholipids.
- PS was concentrated in a precipitated fraction under any conditions, and among them, the PS content in the precipitated phospholipids was 55% or more at amounts of common salt of 10 mmol or less per gram of the phospholipids in the extracts mixture, indicating that PS was efficiently concentrated in the precipitate.
- the recovery rate of PS into the precipitate was 60% or less, and 40% or more thereof remained in the supernatant at amounts of common salt of 0.05 mmol or less.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for producing a phospholipid using transphosphatidylation, which comprises homogenizing a mixture of a raw material phospholipid, a hydroxyl-containing acceptor, phospholipase D, and water in the absence of an organic solvent to obtain a homogenized mixture; and subjecting the homogenized mixture to a transphosphatidylation reaction at 15° C. to 65° C. The homogenized mixture has a lamellar lyotropic liquid crystal structure. An objective phospholipid can be obtained from the homogenized mixture through transphophatidylation without using an organic solvent or calcium.
Description
- This is a continuation application of application Ser. No. 10/344,063 filed Feb. 6, 2003, which is a U.S. national phase application under 35 U.S.C. 371 of International application No. PCT/JP01/06502 (not published in English) filed Jul. 27, 2001.
- The present invention relates to a method for producing an objective phospholipid using transphosphatidylation (phospholipid base exchange reactions).
- Phospholipids such as phosphatidylserines (PSs) and phosphatidylglycerols (PGs) each have their useful physiological or biological functions and specific physical properties and are used in, for example, pharmaceutical preparations, food materials, and emulsifying agents. For example, phosphatidylserines are promising as drugs for prophylaxis and/or therapy of senile dementia and dysmnesia (memory disorder), phosphatidylglycerols are promising as emulsifying agents, and phosphatidylascorbic acids are promising as emulsifying agents and lipoperoxides inhibitors.
- These phospholipids have been conventionally produced by chemical synthesis or by transphosphatidylation using phospholipase D. Among these production methods, enzymatic methods can relatively easily produce phospholipids at relatively low cost and are widely used.
- Methods for producing objective phospholipids by transphosphatidylation (phospholipid base exchange reactions) have been known from a long time ago (Yang, S. F. et al., J. Biol. Chem., 242, p.477, 1967). For example, Kokusho et al. disclose that a reaction product containing phosphatidylserine is obtained by a biphasic reaction in which phospholipase D is allowed to act upon a mixture of a solution of egg-yolk phosphatidylcholine in isopropyl ether with a L-serine aqueous solution containing calcium chloride (Agric. Biol. Chem., 51, p.2515, 1987). It is generally believed that a reaction system in such a biphasic reaction comprises two phases of an oil phase containing a material phospholipid and an aqueous phase containing an acceptor and that transphosphatidylation occurs at the interface between the two phases.
- Japanese Patent No. 2,942,302 describes a homogenous reaction in which a phospholipid preparation containing about 85% of phosphatidylcholine prepared by fractionating soybean lecithin is dissolved in ethyl acetate, the resulting solution is mixed with an ascorbic acid aqueous solution to yield a mixture, and the mixture is allowed to react with phospholipase D to thereby yield a reaction product containing phosphatidyl ascorbate.
- However, the biphasic reaction must be carried out in the presence of solvents (an organic solvent and water) five times or more (volume/weight) as much as the phospholipid and thereby must use a reactor having a volume capacity six times as much as the amount of the phospholipid. In addition, calcium added to accelerate the reaction rapidly forms a salt with the phospholipid. The formed calcium salt is belonging to the category of chemically synthesized substances in Japan and Europe, and the product is thereby difficult to use in food.
- In the homogenous reaction (monophasic reaction), the reaction system contains large amounts of water and yields a phosphatidic acid, as a by-product, due to hydrolytic activity of phospholipase D during a continuous reaction, thus the separation and purification of the objective phospholipid becoming difficult. In addition, the proportion of the acceptor to the phospholipids is limited in the homogenous reaction, and thereby the production amount of the objective reaction product (phospholipid) is limited.
- A patent granted to Fujita et al. (JP-B-7-016426) describes that phosphatidylserine, phosphatidylglycerol, and others are produced by a reverse micelle reaction in which an aqueous phase containing calcium chloride, a hydroxyl-containing acceptor, and phospholipase D and being encapsulated in a reversed micelle is allowed to react with a solution of a raw material phospholipid in an organic solvent (diisopropyl ether, isooctane, cyclohexane, benzene, chloroform-isooctane, n-hexane, or dichloromethane-isooctane).
- In the Japanese Patent Publication, Fujita et al. report that the reverse micelle reaction requires only a small amount of water and thereby suppresses the formation of phosphatidic acids, the problem of the above method. However, the method in question insufficiently yields the objective phospholipid in a yield of at most about 20%, requires complicated operations such as ultrasonic treatment and thus invites problems in operability and cost. The method also requires the
organic solvent 10 times (volume/weight) as much as the phospholipid and must use a reactor having a capacity many times as much as the amount of the phospholipid. - These conventional transphosphatidylation reactions must be carried out in a reaction system containing an organic solvent. However, when product phospholipids are used in, for example, food and pharmaceutical preparations, the organic solvent must not remain in the products and must be completely removed. Accordingly, their production process steps require facilities for the removal of the organic solvent, thus inviting disadvantages in, for example, operability and cost. In particular, such organic solvents cannot be substantially used in the reactions based on the food sanitation law when the products are used in the production of food.
- Demands have therefore been made on methods for producing phospholipids without using organic solvents and/or calcium salts. However, one skilled in the art generally believes that a reaction does not smoothly proceed without using organic solvents and thereby the yield of the objective phospholipid and operability should decrease, since the material phospholipids such as phosphatidylcholines are oil-soluble.
- Accordingly, an object of the present invention is to provide a method for producing phospholipid by transphosphatidylation, using phospholipase D, which can easily produce the objective phospholipid in a high yield without using organic solvents and/or calcium.
- Thus, according to the present invention, the above object can be achieved by a method for producing phospholipid through transphosphatidylation, comprising the steps of homogenizing a mixture of a raw material phospholipid, a hydroxyl-containing acceptor (accepter having one or more hydroxyl groups), phospholipase D, and water in the absence of an organic solvent to obtain a homogenized mixture; and subjecting the homogenized mixture to a transphosphatidylation reaction at a temperature within a range from 15° C. to 65° C.
- In the method according to the present invention, the four components, the raw material phospholipid, the hydroxyl-containing acceptor, phospholipase D, and water, are sufficiently mixed, and the resulting mixture is further homogenized. The homogenized mixture is supposed to have a lamellar lyotropic liquid crystal structure. The term “lamellar lyotropic liquid crystal” means a liquid crystal of a phospholipid bilayer membrane formed by adding water to a phospholipid. In the present invention, it is supposed that the homogenized mixture has an array structure containing the bilayer membrane (sometime a polymolecular layer membrane structure) and an aqueous layer alternately continuously arrayed. The lamellar lyotropic liquid crystal structure can be identified by, for example, microscopic observation of the homogenized mixture under crossed Nicols.
- In this connection, a “lamellar lyotropic liquid crystal structure substantially without phase separation” mentioned later and a “lamellar lyotropic liquid crystal structure with phase separation” are observed as a continuous lamellar structure and as a closed-ring structure floated in an aqueous phase, respectively.
- The lamellar lyotropic liquid crystal structure is generated in the following manner. That is, by adding water to the raw material phospholipid in the homogenization procedure, the interaction between hydrophilic groups in the phospholipid becomes weak, and its crystal structure disintegrates to forme a lamellar liquid crystal. Because of the formation of the lamellar lyotropic liquid crystal structure, water can freely move between layers of the lamellar structure of the phospholipid to make it efficient to supply the acceptor and/or the enzyme and to remove polar heads liberated from the phospholipid, thereby enabling a transphosphatidylation reaction.
- To increase the yield of the reaction product, the entire homogenized mixture must have the lamellar lyotropic liquid crystal structure. For that purpose, the individual components must be homogenized in addition to simply mixed. In other words, the entire homogenized mixture preferably has the lamellar lyotropic liquid crystal structure (i.e., the mixture substantially has the lamellar lyotropic liquid crystal structure) as a result of homogenization for a higher yield of the reaction product.
- A water content in the homogenized mixture affects the formation of the lamellar lyotropic liquid crystal structure. If the water content is within a specific range (e.g., from about 10 wt % to about 100 wt % relative to the amount of soybean phospholipid), the homogenized mixture will have a lamellar (neat) liquid crystal with substantially no phase separation. However, if the water content is excessively higher than the specific range, the homogenized mixture may undergo phase separation to form two phases containing a liquid and a liquid crystal. In the method according to the present invention, the reaction is preferably performed while the homogenized mixture is without phase separation or with substantially no phase separation (hereinafter both are referred to as “lamellar lyotropic liquid crystal structure substantially without phase separation”) for a further higher transfer activity.
- In contrast, in a homogenized mixture containing an excessively large amount of water to thereby invite phase separation (a lamellar lyotropic liquid crystal structure with phase separation), the liquid crystal may constitute discontinuous small granules floating in the solvent. Accordingly, the contact efficiency between water and the phospholipid decreases, thus decreasing transfer activity as compared with the case without phase separation. If the water content is excessively low, the phospholipid may maintain its crystal structure to inhibit the formation of a lamellar lyotropic liquid crystal structure overall the phospholipid to thereby lose the field of an enzymatic reaction. Alternatively, the homogenized mixture may have decreased fluidity and thereby have a deteriorated contact efficiency between the substrate and the enzyme, thus the enzyme cannot efficiently act upon the substrate.
- Organic solvents are preferably not used in the homogenization procedure. If an organic solvent is added during the homogenization procedure, phase separation as in conventional biphasic reactions (not phase separation in the lamellar lyotropic liquid crystal structure but separation between an oil phase and an aqueous phase) may be enhanced. In addition, the addition of an organic solvent invites various disadvantages as described above.
- Raw material phospholipids for use in the present invention include any of phospholipid-containing natural products, extracts or purified extracts of such natural products, and synthetic phospholipids. Examples of the phospholipids include, but are not limited to, soybean lecithin, rapeseed lecithin, egg yolk lecithin, corn lecithin, cottonseed lecithin, purified products of these lecithins; phosphatidylcholines (hereinafter briefly referred to “PC(s)”), phosphatidylethanolamines (hereinafter briefly referred to as “PE(s)”), and mixtures of these substances. Among them, soybean lecithin, rapeseed lecithin, egg yolk lecithin, and purified products of these lecithins are preferred for their availability and cost
- Hydroxyl-containing acceptors for use in the present invention are not specifically limited as long as they can receive or accept a phosphatidyl group of the raw material phospholipid in the presence of phospholipase D. Such hydroxyl-containing acceptors include, for example, serine, glycerol, L-ascorbic acid, glucose, choline, ethanolamine, 1-amino-2-propanol, and 1-o-methyl-glycoside. Among them, serine, choline, L-ascorbic acid, glucose, and glycerol are preferred for a higher yield of the objective product, of which serine and glycerol are typically preferred.
- Phospholipase Ds (hereinafter briefly referred to as “PLD(s)”) for use herein are not specifically limited as long as they have ransphosphatidylation activity and include, for example, free or chemically modified PLDs, and immobilized enzymes immobilized to a carrier such as ion exchange resins and silica gel. Among them, free PLDs are preferred for a further higher yield of the reaction product.
- More specifically, any of PLDs derived from plants or vegetables such as cabbage and carrot, PLDs derived from microorganisms such as mycobacteria, bacteria, yeasts, and fungi (molds), and PLDs derived from animals can be advantageously used. They may be prepared products prepared according to a conventional procedure or commercially available products such as a cabbage-derived PLD (e.g., Product Number P 7758, Sigma Chemical Company), peanut-derived PLD (e.g., Product Number P 0515, Sigma Chemical Company), and a PLD derived from Streptmyces chromofuscus.
- According to the present invention, the raw material phospholipid, the hydroxyl-containing acceptor, PLD, and water are initially mixed, and the resulting mixture is further subjected to a homogenization procedure. The homogenization procedure herein means homogenous dispersion of the four components in the mixture by the application of physical force by means of, for example, physical agitation, ultrasonic treatment, etc. More specifically, homogenization treatments using a Vibromixer, automatic mortar, Homo Mixer, Physcotron, food processor, or sonicator alone or in combination can be employed. If the amount of the mixture is small, it may be kneaded using, for example, a microspatula. The four components may be mixed and homogenized separately in time or simultaneously. For example, one of the four components may be mixed and homogenized with another, and this procedure is repeated. It is also acceptable that two, three or four of the components are mixed or dissolved in advance, and then the resulting mixture or solution is ultimately homogenized.
- If the homogenization procedure is not performed in the method of the present invention, the yield of the objective phospholipid significantly decreases. This is probably for the following reasons. That is, the raw material phospholipid is generally a hard paste at room temperature, and the entire mixture cannot have a lamellar lyotropic liquid crystal structure by simply mixing the other components. As a result, the individual components come in contact with one another at a lower frequency to thereby decrease the yield of the objective product. Accordingly, the mixture of the components must be applied with physical force to such an extent as to disperse the individual components and must be subjected to a “homogenization procedure”.
- The hydroxyl-containing acceptor can be used as an aqueous solution or as a powder in the homogenization procedure. PLD is used as a solution in a small amount of water or as a powder. In this procedure, if the other three (the raw material phospholipid, PLD, and water) than the acceptor have been mixed in advance, phosphatidic acid (hereinafter referred to as “PA”) is by-produced. Accordingly, it is preferred that the raw material phospholipid is mixed with the acceptor in advance, and the resulting mixture is then mixed with the other components, or the four components are mixed and homogenized simultaneously.
- As is described above, the amount of water content in the homogenization procedure affects the phase separation of the lamellar lyotropic liquid crystal structure and the yield of the reaction product phospholipid and is preferably controlled and adjusted to prevent the phase separation. While depending on the type of the raw material phospholipid, the water content in the lamellar lyotropic liquid crystal structure is preferably from 10 wt % to 100 wt % and more preferably from 20 wt % to 60 wt % relative to the amount of the raw material phospholipid to substantially prevent the phase separation. The term “water content” in the lamellar lyotropic liquid crystal structure as used herein means the amount of water in the homogenized mixture after removing water separated during the homogenization procedure and can be determined by, for example, a conventional Karl Fischer technique. The separated water may be removed by decantation or centrifugal separation, for example, at 150 g for about 1 minute.
- It is not necessarily appropriate to specify a preferred amount of the acceptor, since it varies depending on the type of the acceptor. For a better yield of the reaction product and operability, the amount is preferably from about 0.3 mole to about 10 moles and more preferably from about 4 moles to about 8 moles per 1 mole of the raw material phospholipid. If an excessively large amount (exceeding 10 moles) of the acceptor is added, the recovery of an unreacted acceptor may require increased efforts. In contrast, if the amount is excessively small, the yield of the objective product may decrease.
- More specifically, the amount of serine as the hydroxyl-containing acceptor is preferably from 5 wt % to 150 wt %, and more preferably from 50 wt % to 100 wt % relative to the amount of the raw material phospholipid. The amount of glycerol as the hydroxyl-containing acceptor is preferably from 10 wt % to 200 wt %, and more preferably from 20 wt % to 100 wt %.
- The amount of PLD is not specifically limited, can be determined depending on, for example, the reaction time in the subsequent reaction step and is generally from about 500 to 100,000 units per kg of the phospholipid.
- A temperature in the homogenization procedure is not specifically limited and is preferably from about 15° C. to 65° C. If the temperature is lower than 15° C., it may require extra energy to cool the reaction system, and the mixture may not sufficiently be homogenized. If it is higher than 65° C., the phospholipid may become unstable.
- In addition to the aforementioned components, an edible oil and/or fat can be added during the homogenization procedure within ranges not deteriorating the lamellar lyotropic liquid crystal structure. Although the addition of such an edible oil and/or fat enhances the conversion of the lamellar lyotropic liquid crystal structure into a biphasic system as organic solvents, a small amount of the edible oil and/or fat increases the fluidity of the homogenized mixture to thereby increase the yield of the objective phospholipid. Such edible oils and fats include, but are not limited to, safflower oil, soybean oil, corn oil, rapeseed oil, cottonseed oil, sunflower oil, safflower oil, sesame oil, olive oil, hempseed oil, perilla oil, theobroma oil (cacao butter), coconut oil, and other vegetable oils; butter oil, fish oil, lard, beef tallow, and other animal oils; and middle-chain triacylglycerols (MCTs). Each of these oils and fats is added alone or in combination to the raw material phospholipid to impart fluidity thereof. Among them, MCTs, theobroma oil, and soybean oil are preferred to further improve the yield of the objective product
- While depending on the types of the raw material phospholipid and the added edible oil and/or fat, the amount of the edible oil and/or fat is preferably less than or equal to an equivalent amount and more preferably from 5 wt % to 15 wt % relative to the amount of the raw material phospholipid.
- It is possible to add an organic solvent such as hexane or ether for the same purpose within ranges not deteriorating the lamellar lyotropic liquid crystal structure, but is not preferred as described above.
- Some of advantages of the present invention will be described hereinafter. Conventional transphosphatidylation reactions have been performed according to any of biphasic reactions, reversed micelle reactions, and homogenous phase reactions. The biphasic reactions and reversed micelle reactions require a solvent five times (volume/weight) or more as much as the phospholipid to maintain their reaction systems. In contrast, the method of the present invention requires a solvent only one time as much as the phospholipid and can thereby use a reactor having a smaller capacity for the production of the phospholipid in the same amount as in the conventional equivalents.
- The homogenous phase reactions require a solvent two times (volume/weight) or more as much as the phospholipid and thereby require a reactor having a capacity three times (volume/weight) or more as much as the phospholipid. In addition, the amount of the acceptor is limited to maintain their homogenous phase, and it is difficult to obtained a reaction product containing the objective compound in a high content. For example, to produce PS, the amount of serine that can be added to 1 kg of the phospholipid is 0.15 kg and the PS content in the reaction products phospholipids is at most 35%. In contrast, according to the method of the present invention, 1 kg or more of serine can be added to 1 kg of the phospholipid, and thereby reaction products containing 48% or more of PS in the phospholipids can be obtained. Specifically, the method of the present invention can reduce the capacity of a reactor to produce an equivalent amount of the objective phospholipid and can yield reaction products containing the objective compound in a high content as compared with the homogenous reactions.
- Each of the conventional transphosphatidylation reactions must be performed in the presence of an organic solvent such as an ether, toluene, n-hexane, or ethyl acetate in their reaction system. However, the method according to the present invention does not require organic solvents and is therefore advantageous in the production of the phospholipids for food and other substances in which the use of organic solvents is restricted. Further, according to the present invention, the reaction proceeds even without the addition of calcium ions in contrast to the conventional methods. While not being clarified, this is probably because the reaction is performed in a liquid crystal according to the present invention and thereby the raw material phospholipid becomes structurally susceptible to transphosphatidylation reactions regardless of the presence or absence of calcium ion. In contrast, the conventional biphasic reaction is performed in a liquid.
- According to the present invention, the homogenized mixture thus obtained is subjected to a transphosphatidylation reaction in the absence of an organic solvent to yield the objective phospholipid. The reaction is performed at a temperature preferably within a range from 15° C. to 65° C. and more preferably from 45° C. to 55° C. If the reaction temperature is lower than 15° C., the reaction may not be enhanced to proceed to thereby deteriorate the yield of the objective phospholipid. If the reaction temperature is higher than 65° C., side reactions of phospholipid, such as decomposition and/or oxidation of the produced phosphatidylserine, may occur.
- A reaction time is not specifically limited, can be appropriately selected depending on the reaction temperature, the types and amounts of the components and is preferably from about 1 to 48 hours for a better yield of the objective phospholipid and less by-production of PA.
- The transphosphatidylation reaction can be performed left stand or with stirring. For example, the reaction can be performed with stirring using a tabletop universal mixer (e.g., KINMIX MAJOR (trademark), Type-KM-230).
- In the production of phospholipids according to the method of the present invention, a lamellar liquid crystal structure without phase separation is formed entirely in the homogenized mixture by mixing an appropriate amount of water with the raw material phospholipid, and water can freely move between layers of the lamellar structure of the phospholipid, thereby efficiently supplying the hydroxyl-containing acceptor and/or the enzyme as well as efficiently removing polar heads liberated from the phospholipid. Accordingly, it is possible to achieve the transphosphatidylation reaction at high activity, and the objective phospholipid can be easily obtained in high yield at low cost.
- Phospholipids obtained according to the present invention may contain impurities derived from the raw material phospholipid and the acceptor, and other substances in addition to by-product PA. The obtained phospholipid is therefore often a phospholipid mixture containing the objective phospholipid, other phospholipids and impurities.
- The phospholipid obtained by the transphosphatidylation is preferably used after the removal of such impurities by subjecting the same to an appropriate purification process but can be used while containing impurities derived from the raw materials or formed in the production processes as long as the impurities do not invite problems in administration or deteriorate the advantages. The product can be purified by any technique such as fractionation using a solvent and chromatography in appropriate combination according to a conventional procedure.
- The phospholipids obtained according to the present invention can be administered in the form of, for example, pharmaceutical preparations, food, or cosmetics. For example, to be used in the form of pharmaceutical preparations to utilize the biological functions of the phospholipids, they can be orally administered in the dosage form of, for example, capsules, granules, tablets, powders, and other solid preparations; and syrups, and other liquid preparations. Alternatively, they can be administered in the form of, for example, injections, dermatologic external preparations, rectal infusions, and other non-oral preparations.
- In production of these preparations, additional pharmaceutically acceptable components can be used according to necessity. Such components include, for example, lactose, starches, crystalline cellulose, calcium lactate, magnesium aluminometasilicate, silicic anhydride, and other excipients; sucrose, hydroxypropylcellulose, polyvinylpyrrolidone, and other binders; carboxymethylcellulose, carboxymethylcellulose calcium, and other disintegrators; magnesium stearate, talc, and other lubricants.
- When the phospholipid obtained according to the method of the present invention is used in food in the expectation of similar biological functions, such food can be appropriately produced according to a conventional procedure by adding the phospholipid as intact or after purification to oils and fats, tablet or granular confectionery, fermented milk, candies, spices, fish and vegetables flakes to sprinkle on cooked rice, and other food and drinks.
- An appropriate amount of the phospholipids obtained by the method of the present invention can be used in the form of these pharmaceutical preparations and food. To obtain the biological functions of the phospholipids, the amount thereof may be such as to yield the functions and not to invite problems such as overdose. For example, the compositional amount of phosphatidylserine produced as the phospholipid is such an amount as to take in from about 50 mg to 1,000 mg a day.
- The phospholipids obtained by the method according to the present invention can also be used as emulsifying agents. In this case, the emulsifying agent may be added to, for example, pharmaceutical preparations, food, and cosmetics in an amount preferably from 0.01% to 10%.
- Among phospholipids obtained by the method according to the present invention, a phosphatidylserine can be easily purified and concentrated from a phospholipid mixture containing the phosphatidylserines by dissolving the phospholipid mixture in an alcohol to yield a solution, adding a metallic salt to the solution to insolubilize the phosphatidylserines, and separating the insolubilized matter.
- Such metallic salts for use herein include, but are not limited to, lithium salts, sodium salts, potassium salts, calcium salts, magnesium salts, and other metallic salts, as well as natural products containing any of these metallic salts in abundance, such as common salt, bittem, brine, dolomite, and edible powdery mother of pearl. Among them, lithium salts, sodium salts, and potassium salts are preferred for efficient concentration, of which lithium chloride, sodium chloride, and potassium chloride are typically preferred. Each of these metallic salts can be used alone or in combination.
- The amount of the metallic salt(s) is not specifically limited as long as phosphatidylserine can be precipitated and is preferably from 0.15 to 10 mmol, and more preferably from 0.5 to 5 mmol per gram of the phospholipid for a higher recovery rate of the phosphatidylserines and a higher content of the phosphatidylserines in the precipitate.
- Any alcohol can be used herein as long as it can dissolve the phospholipid mixture, of which methyl alcohol, ethyl alcohol, butyl alcohol, propyl alcohol, isopropyl alcohol, and other lower alcohols are preferred. Mixtures of these alcohols can also be used. Ethyl alcohol can be easily applied to food with less problems in safety and is typically advantageously used.
- The concentration of the phospholipid mixture in the alcohol is not specifically limited, is preferably equal to or more than such a concentration that the mixture can be completely dissolved in the alcohol and is preferably from 1 to 50%, and more preferably from 2 to 20% relative to the weight of the alcohol for efficient concentration procedure of the phosphatidylserines and for higher operability.
- The phosphatidylserines can be concentrated from the phospholipid mixture, for example, in the following manner. Initially, the phospholipid mixture prepared by transphosphatidylation and containing other phospholipids in addition to the phosphatidylserines is dissolved in an alcohol such as ethyl alcohol. In this procedure, dissolution conditions such as dissolution temperature are not specifically limited and can be appropriately selected depending on the types and amounts of components of the mixture and other parameters.
- In the resulting solution, the phosphatidylserines, PC, PA, and other phospholipids are extracted into a solvent layer, but some insoluble matters may form. Accordingly, the metallic salt is added after removing such precipitates, aggregates, and other insoluble matters from the solvent by means of, for example, centrifugal separation and/or filtration. If the insoluble matters include a small amount of phosphatidylserine, extraction operation with the alcohol can be repeated several times.
- Next, the metal salt is added to the alcohol solution to thereby fractionate the phosphatidylserines extracted in the solvent layer. Specifically, most of the other phospholipids than the phosphatidylserines in the solvent layer do not precipitate by the addition of the metal salt, but most of the phosphatidylserines precipitates, and thus the phosphatidylserines can be concentrated by recovering the precipitated phosphatidylserine. The metal salt can be added as a powder or a solution in a solvent such as water or an alcohol. Conditions in the procedure are not specifically limited and can be appropriately selected depending on, for example, the types and amounts of components of the mixture. More specifically, the mixture with the metallic salt is held at 10° C. to 30° C. for 30 minutes or longer to thereby insolubilize PS.
- The phosphatidylserines insolubilized as a result of addition of the metallic salt can be recovered by a means such as centrifugal separation, filtration, and standing separation. The phosphatidylserines can be further purified by a conventional purification means such as column chromatography. The phosphatidylserines concentrate according to the present invention contains significantly reduced amounts of other phospholipids and other components and can thereby be relatively easily purified.
-
FIG. 1 is a diagram of test results on optimum amounts of MCT with the ordinate A showing the PS production rate (%) and the abscissa B showing the added amount ratio (%) of MCT to the phospholipids. -
FIG. 2 is a diagram of test results on optimum amounts of MCT with the ordinate C showing the ratio (%) of MCT to the phospholipids and the abscissa D showing the PS production rate (%). -
FIG. 3 is a diagram of test results on molar ratios of serine to phospholipids in a homogenized mixture with the ordinate E showing the PS production rate (%) and the abscissa F showing the molar ratio (mol/mol) of serine to the phospholipids. -
FIG. 4 is a diagram of test results on weight ratios of water to phospholipids in a homogenized mixture with the ordinate G showing the PS production rate (%) and the abscissa H showing the ratio (% by weight) of water to the phospholipids. -
FIG. 5 is a diagram of test results on weight ratios of water to phospholipids in a homogenized mixture with the ordinate I showing the PS production rate (%) and the abscissa J showing the ratio (% by weight) of water to the phospholipids. -
FIG. 6 is a diagram of test results on weight ratios of water to phospholipids in a homogenized mixture with the ordinate K showing the PS production rate (%) and the abscissa L showing the ratio (% by weight) of water to the phospholipids. -
FIG. 7 is a diagram showing production rates of PS at different reaction temperatures with the ordinate M showing the PS production rate (%) and the abscissa N showing the temperature (°C.). - The present invention will now be explained in detail with reference to preferable embodiments below, which are not intended to limit the scope of the invention.
- A total amount of 97 g of 6.7 M L-serine aqueous solution (with or without 0.18 M calcium chloride) was kneaded (homogenized) with 100 g of a mixture of soybean lecithin and cocoa butter (NATHIN 250, trademark, available from Central Soya Company, Inc.) in an automatic mortar (Model ANM-150) and was held at 55° C. A total of amount 2.0 mL of an enzyme mixture containing 800 units of phospholipase D-Y1 derived from an actinomycete belonging to Streptomyces (PLD-Y1, product name, available from Yakult Honsha Co., Ltd.) was kneaded (homogenized) with the kneaded mixture in an automatic mortar, and a reaction was performed in the absence of organic solvents. The transphosphatidylation reaction was performed with stirring at 55° C. for 17 hours and was complete.
- Analyses of reaction products by silica gel thin-layer chromatography revealed that 47.9% by mole of total phospholipids was converted into phosphatidylserines when 0.18 M calcium chloride was added, and that 44.5% by mole of the total phospholipids was converted into phosphatidylserines even in the absence of calcium chloride. These results show that the transphosphatidylation reaction can proceed in this reaction system even without the addition of calcium. The homogenized mixture before the initiation of the reaction was observed with a microscope under crossed Nicols and was found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation”.
- As is described above, the present invention provides a method for performing a transphosphatidylation reaction without the use of organic solvents. Specifically, transphosphatidylated products can be efficiently produced by homogenizing an aqueous solution containing the hydroxyl-containing acceptor and phospholipase D with the phospholipid before reaction.
- The method does not require any organic solvent. However, an oil-soluble substance other than organic solvents can be added to the phospholipid to thereby further improve the operability. Such oil-soluble substances include, but are not limited to, safflower oil, soybean oil, corn oil, rapeseed oil, cottonseed oil, sunflower oil, safflower oil, sesame oil, olive oil, hempseed oil, perilla oil, theobroma oil (cacao butter), coconut oil, and other vegetable oils; butter oil, fish oil, lard, beef tallow, and other animal oils; MCTs as glyceride derivatives prepared from middle-chain fatty acids as starting materials; and other edible oils and fats.
- The results of Example 1 show that the transphosphatidylation reaction proceeds even without the addition of calcium. However, the effects of the addition of calcium were further investigated. Specifically, individual components were mixed with or without the addition of calcium as shown in Table 1 while the molar ratio of serine to the phospholipid was set at 1 or 5. The resulting mixture was kneaded (homogenized) using a microspatula and was allowed to react at 55° C. for 18 hours. In this procedure, a sample with the molar ratio of 1 employed 2.5 M serine aqueous solution, and one with the molar ratio of 5 employed 4.5 M serine aqueous solution. More specifically, NATHIN 250 and the serine aqueous solution containing, if any, calcium were mixed, and the resulting mixture was treated with the PLD-Y1 aqueous solution to initiate a reaction.
- The amounts of reaction products were determined in the same manner as in Example 1. Table 2 shows that, the production rate of PS without the addition of calcium was slightly lower than but substantially the same as that with the addition of calcium. Homogenized mixtures before reaction were subjected to microscopic observation under crossed Nicols and were found to have a lamellar lyotropic liquid crystal structure substantially without phase separation. In the tables, the abbreviations PA, PE, and PI represent phosphatidic acid, phosphatidylethanolamine, and phosphatidylinositol, respectively.
TABLE 1 Molar ratio of serine to phospholipids 1 5 Addition of calcium no yes no yes NATHIN 250 (g) 10 10 10 10 Serine (g) 0.8 0.8 4.0 4.0 Calcium chloride (g) — 0.04 — 0.19 Water (g) 2.6 2.6 5.7 5.7 PLD-Y1 (units) 82.2 82.2 82.2 82.2 -
TABLE 2 Molar ratio of serine to phospholipids 1 5 Addition of calcium no yes no yes PA (mole %) 13.0 11.8 10.9 11.0 PE (mole %) 4.7 3.3 3. 2.7 PS (mole %) 34.5 35.5 44.2 47.4 PC (mole %) 31.0 32.2 25.0 21.4 Other phospholipids (mole %) 16.9 17.1 16.7 17.5 - These results show that good yields can be obtained according to the present invention regardless of the presence or absence of calcium. Accordingly, the method of the present invention does not require the addition of calcium to its reaction system in contrast to most of conventional transphosphatidylation reactions using an organic solvent.
- A total of 50 g of NATHIN 250 (available from Central Soya Company, Inc.) was dissolved in 500 mL of a reagent chemical acetone by heating to 60° C., and the solution was cooled to 15° C. The resulting precipitate was dissolved in 300 mL of a reagent chemical acetone by heating to 60° C., the solution was then cooled to 15° C. and thereby yielded a precipitate comprising phospholipids alone with no triglyceride. To 6 g of a dried product of the precipitate (hereinafter referred to “NATHIN 250/acetone precipitate”) was kneaded (homogenized) with 5.8 g of 4.5M L-serine aqueous solution (with or without the addition of 0.18 M calcium chloride), and the kneaded article was held at 55° C. The kneaded article was further kneaded (homogenized) with 0.2 mL of an enzyme mixture containing 49.3 units of Phospholipase D Y-1 (available from Yakult Honsha Co., Ltd.) using a microspatula, and the kneaded article was immediately subjected to a reaction at 55° C. for 17 hours to thereby complete a transphos-phatidylation reaction.
TABLE 3 PS Production Reaction Using NATHIN 250/acetone Precipitate as Substrate (Substrate Composition) Molar ratio of serine to phospholipids 5 Addition of calcium no yes NATHIN 250/acetone precipitate (g) 6.0 6.0 Serine (g) 2.4 2.4 Calcium chloride (g) — 0.1 Water (g) 3.4 3.4 PLD-Y1 (units) 49.3 49.3 - Analyses of obtained reaction products by silica gel thin-layer chromatography revealed that 41.7% of total phospholipids was converted into phosphatidylserines when 0.18 M calcium chloride was added. However, 35.1% of total phospholipids was converted into phosphatidylserines even without the addition of calcium chloride. Homogenized mixtures before the initiation of the reaction were subjected to microscopic observation under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation”. Tables 3 and 4 show compositions of substrates and the results of PS transphatidylation reactions using the acetone precipitate as a substrate, respectively.
TABLE 4 PS Production Reaction Using NATHIN 250/acetone Precipitate as Substrate (Phospholipids Compositions of Purified Products) Molar ratio of serine to phospholipids 5 Addition of calcium no yes PA (mole %) 9.0 10.2 PE (mole %) 2.7 1.9 PS (mole %) 35.1 41.7 PC (mole %) 35.3 28.8 Other phospholipids (mole %) 17.9 17.4 - Raw material phospholipids were prepared by kneading 1 to 9% by weight of MCT (Panasate 810, trademark, available from Nippon Oil And Fats Co., Ltd.) into NATHIN 250/acetone precipitate. Each of the material phospholipids was further kneaded with 200 mg of serine and 200 mL of water (molar ratio of phospholipids to water 0.4) relative to 500 mg of NATHIN 250/acetone precipitate. The kneaded article was further kneaded (homogenized) with a PLD-Y1 aqueous solution (4.1 units per 15 mL) using a microspatula and was allowed to react at 55° C. for 17 hours. Phosphatidylserines after the completion of reaction were determined by silica gel thin-layer chromatography.
-
FIG. 1 is a diagram showing test results on optimum amounts of MCT. As shown inFIG. 1 , by adding 50 mg (9% relative to phospholipids) of MCT, the PS production rate increases from 34.7% to 40.4% as compared with the case where MCT is not added, verifying effects of the addition of MCT. Reactions were performed in the same manner with a varying ratio of MCT of 10% to 40%.FIG. 2 is a diagram showing test results on optimum amounts of MCT. As shown inFIG. 2 , the PS production rate increases in all the samples with 10% to 40% of MCT. Apparently.FIGS. 1 and 2 indicate that the amount of MCT is preferably from 9% to 40%. Homogenized mixtures before the initiation of the reaction were observed with a microscope under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation”. - To 500 mg of NATHIN 250 was added 2.5 M serine aqueous solution containing 0.18 M calcium chloride in a varying molar ratio of serine to phospholipids from 0.1 to 15, and the mixture was mixed in a mixer while warming on a water bath at 60° C. After cooling the water bath to 55° C., the reaction substrate was further mixed and homogenized with a PLD-Y1 aqueous solution using a microspatula or Vibromixer. The homogenized mixture was allowed to react at 55° C. for 17 hours, and the phospholipid composition of reaction products was analyzed by silica gel thin-layer chromatography.
-
FIG. 3 shows that the PS content in the reaction products is 20% or more at molar ratios of serine to phospholipids of 0.3 or more, indicating that these are suitable conditions for the production of PS. In particular, molar ratios of 4 or more can achieve PS contents of 45% or more and are typically preferred as substrate compositions. However, if the molar ratio is 10 or more, the production of PS does not increase with an increasing amount of serine, indicating that an upper limit of the molar ratio for efficient production of phosphatidylserines is about 10. Homogenized mixtures (at molar ratios from 0.3 to 10) before reaction were subjected to microscopic observation under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation”. - The amount of water relative to phospholipids was 100 parts by weight or more at molar ratios of serine of 6 or more. However, the amount of water in the homogenized mixtures as determined by the Karl Fischer's technique was 100 parts by weight or less after removal of separated water by decantation.
- A total amount of 200 mg each of powdery L-serine was sufficiently mixed with 500 mg of soybean lecithin (NATHIN 250/acetone precipitate, or PC 80 available from Croklaan B. V.) or egg yolk lecithin (PL-100LE, available from Q.P. Corporation) in a mortar heated at 60° C. The mixture was further kneaded with distilled water in water contents shown in FIGS. 4 to 6 and was held at 55° C. A total of 0.015 mL of an enzyme mixture containing 4.1 units of PLD-Y1 (available from Yakult Honsha Co., Ltd.) was kneaded (homogenized) with the kneaded article using a microspatula, and a transphosphatidylation reaction was performed at 55° C. for 17 hours while left stand and was complete. The water contents in the homogenized mixtures were determined by the Karl Fischer's technique.
- Obtained reaction products were analyzed by silica gel thin-layer chromatography. FIGS. 4 to 6 are diagrams of results with the ordinate showing PS contents (%) in the reaction products and the abscissa (logarithmically plotted) showing the ratio (% by weight) of water to soybean lecithin.
-
FIG. 4 shows that when NATHIN 250/acetone precipitate was used as a raw material phospholipid, PS was not produced at a weight ratio of water to the phospholipids in the homogenized mixture of 3%, but 10% or more of the phospholipid was converted into PS at weight ratios from 10% to 100%, indicating that these weight ratios are suitable for the production of PS. A total of 30% or more of the phospholipid was converted into PS at weight ratios of water to the phospholipids from 20% to 70%, indicating that these weight ratios are optimum for the production of PS. Homogenized mixtures were subjected to microscopic observation under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation” at weight ratios of water to the phospholipids from 10% to 100%, suitable for the production of PS. -
FIG. 5 shows that when PC 80 was used as a raw material phospholipid, PS was not produced at a weight ratio of water to the phospholipids in the homogenized mixture of 8%, but 10% or more of the phospholipid was converted into PS at weight ratios from 10% to 60%, indicating that these weight ratios are suitable for the production of PS. A total of 20% or more of the phospholipid was converted into PS at weight ratios of water to the phospholipids from 20% to 40%, indicating that these weight ratios are optimum for the production of PS. Homogenized mixtures were subjected to microscopic observation under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation” at weight ratios of water to the phospholipids from 10% to 60%, suitable for the production of PS. -
FIG. 6 shows that when the egg yolk lecithin was used as a raw material phospholipid, PS was not produced at a weight ratio of water to the phospholipids in the homogenized mixture of 8%, but 10% or more of the phospholipid was converted into PS at weight ratios from 15% to 40%, indicating that these weight ratios are suitable for the production of PS. A total of 20% or more of the phospholipid was converted into PS at weight ratios of water to the phospholipids from 20% to 35%, indicating that these weight ratios are optimum for the production of PS. Homogenized mixtures were subjected to microscopic observation under crossed Nicols and were found to have a “lamellar lyotropic liquid crystal structure substantially without phase separation” at weight ratios of water to the phospholipids from 15% to 40%, suitable for the production of PS. - Each 490 mg of aqueous solutions of acceptors indicated in Table 5 was mixed with 500 mg of PC 80 on a water bath at 60° C., the mixture was kneaded (homogenized) with 50 mL of an aqueous solution containing 13.7 units of a PLD (PLD-Y1) using a microspatula, and the kneaded article was allowed to react at 55° C. for 18 hours. Transphosphatidylation reaction products were analyzed by silica gel thin-layer chromatography.
TABLE 5 Transfer Reactions Using Acceptors other than Serine Concentration of Production rate of aqueous solution acceptor transferred Acceptor as used % (w/w) pH lecithin (%) Glycerol 50 5.9 42.7 L-Ascorbic acid 41 5.0 9.4 Magnesium ascorbate 17 6.7 0.0 phosphate ester Sodium ascorbate 50 7.0 0.0 phosphate ester Inositol 17 6.5 0.0 Glucose 50 5.0 13.3 Trehalose 50 5.3 0.0 - Table 5 shows production rates of transferred products after transfer reactions using each of the acceptors. Table 5 demonstrates that corresponding transphosphatidylated products (phosphatidylglycerol: 42.7%, phosphatidylascorbic acid: 9.4%, phosphatidylglucose: 13.3%) were produced when glycerol, L-ascorbic acid, and glucose were each used as the acceptor. In contrast, no transphosphatidylated product was produced when inositol, ascorbate phosphates, and trehalose were used.
- A total of 490 mg each of 4.5 M serine aqueous solution was added to 500 mg of NATHIN 250/acetone precipitate (PL) or of a phospholipid substrate (PL+TG) comprising 450 mg of NATHIN 250/acetone precipitate and 50 mg of MCT, the resulting mixture was kneaded at 60° C., was further kneaded (homogenized) with 15 mL of an aqueous solution containing 4.1 units of PLD-Y1 using a microspatula and was allowed to react at temperatures from 15° C. to 65° C. in increments of 10° C. for 18 hours. Transphosphatidylated products were analyzed by silica gel thin-layer chromatography.
-
FIG. 7 is a diagram showing production rates of PS at different reaction temperatures and shows that the production rate of PS at 45° C. was 43% and did not change with an elevating temperature when the substrate containing NATHIN 250/acetone precipitate and MCT was used. - When the substrate containing NATHIN 250/acetone precipitate alone was used, the production rate of PS was 30.1% at 45° C. and 38.7% at 65° C., indicating that a more satisfactory result was obtained with an increasing reaction temperature. However, it is speculated that the upper limit of the reaction temperature is 65° C., since PS production decreases and the phospholipids may be deteriorated or decomposed at reaction temperatures exceeding 65° C.
- A total of 490 mg of 4.5 M serine aqueous solution (containing, if any, 9.3 mg of calcium) was mixed with 500 mg of NATHIN 250 at 55° C. After cooling to 45° C., the reaction mixture was treated with 200 mL of a liquid enzyme mixture (0.6 units per milliliter) of Brussels sprout PLD at 45° C. for 18 hours. The Brussels sprout PLD had been separately prepared according to a conventional procedure.
- As a result, a reaction did hardly proceed without the addition of calcium, but proceeded and thereby yielded reaction products containing 6.2% of PS with the addition of calcium.
- With 200 g of soybean lecithin containing 40% of PC were kneaded 190 g of a serine aqueous solution containing 70 g of serine in 120 g of water and 10 mL of an aqueous solution (24 mg/mL) of phospholipase D (PLD-Y1, available from Yakult Honsha Co., Ltd.). The kneaded article was allowed to react at 55° C. for 5 hours and thereby yielded a reaction product containing 46.7% of PS in phospholipids.
- A total of 5.0 g of the reaction product was extracted with 20 mL of ethyl alcohol at 45° C., and the residue (precipitate) was further extracted with two portions of 5 mL of ethyl alcohol. Three extracts were mixed, 5 mL of which was treated with 0.20 mL of 25% common salt (sodium chloride) aqueous solution, was heated to 45° C., was left stand at room temperature and thereby yielded a precipitate. As a result, the precipitate contained 62.1% of PS on dried solid matter basis, whereas a supernatant contained 3.3% of PS, indicating that PS was efficiently concentrated in the precipitated.
- A total of 50 mg of powdery sodium acetate was added to 5 mL of the mixture of the extracts obtained in Example 10, was heated to 45° C., was left stand at room temperate and thereby yielded a precipitate. As a result, the precipitate contained 61.8% of PS on dried solid matter basis, whereas a supernatant contained 3.5% of PS, indicating that PS was efficiently concentrated in the precipitate as in the use of the common salt aqueous solution.
- A 25% common salt aqueous solution was added to the mixture of the extracts obtained in Example 10 and thereby yielded insolubilized PSs. The amounts of PSs in the precipitated phospholipids and in the recovered precipitate were determined. Table 6 shows the relationship among the amount of common salt, the recovery rate of PS in the precipitate and the PS content in the phospholipids.
- As shown in Table 6, PS was concentrated in a precipitated fraction under any conditions, and among them, the PS content in the precipitated phospholipids was 55% or more at amounts of common salt of 10 mmol or less per gram of the phospholipids in the extracts mixture, indicating that PS was efficiently concentrated in the precipitate. The recovery rate of PS into the precipitate was 60% or less, and 40% or more thereof remained in the supernatant at amounts of common salt of 0.05 mmol or less. These results show that PS can be concentrated into a precipitate at any amount of common salt but is practically sufficiently concentrated at amounts of common salt from 0.15 to 10 mmol per gram of phospholipids dissolved in an alcohol.
TABLE 6 Relation between Amounts of Common Salt and PS Recovery Rate/PS Contents in Phospholipids Common PS content in PS content in salt*1) PS recovery precipitated supernatant (mmol/g) rate*2) (%) PL*3) (%) PL*4) (%) None — — 43.2 0.05 53.7 64.7 33.4 0.15 73.8 66.7 28.2 0.25 80.4 69.3 18.0 0.50 96.2 63.8 6.2 1.25 97.4 63.5 4.3 2.5 96.6 62.7 6.1 5 97.1 59.8 6.4 10 95.7 55.0 10.5 25 97.8 47.2 12.0 50 97.7 46.6 13.5
*1)Ratio of amount of common salt per unit weight of phospholipids (mmol/g)
*2)PS recovery rate into precipitated fractions (%)
*3)PS content in precipitated phospholipids (%)
*4)PS content in supernatant phospholipids (%)
Claims (11)
1. A method for producing a phospholipid by transphosphatidylation comprising:
homogenizing a mixture of a raw material phospholipid, a hydroxyl-containing acceptor, phospholipase D and water in the absence of an organic solvent to obtain a homogenized mixture; and
subjecting said homogenized mixture to a transphosphatidylation reaction at a temperature within a range from 15° to 65° C.
2. The method according to claim 1 , wherein said homogenized mixture substantially has a lamellar lyotropic liquid crystal structure.
3. The method according to claim 1 , wherein the content of water in said homogenized mixture is adjusted within a range from 10 wt % to 100 wt % relative to the weight of the raw material phospholipid.
4. The method according to claim 1 , wherein the content of said hydroxyl-containing acceptor is adjusted within a range from 0.3 mole to 10 moles per 1 mole of the raw material phospholipid in said homogenization.
5. The method according to claim 1 , wherein said hydroxyl-containing acceptor is at least one hydroxyl-containing acceptor selected from the group consisting of serine, glycerol, L-ascorbic acid, glucose and choline.
6. The method according to claim 1 , wherein said hydroxyl-containing acceptor is serine, which yields a phosphatidylserine.
7. The method according to claim 1 , which further comprises adding an edible oil and/or a fat during said homogenization.
8. The method according to claim 6 , further comprising the steps of:
dissolving the phospholipid which contains said phosphatidylserine in an alcohol to obtain a solution; and
carrying out an insolubilization by adding a metallic salt to said solution to insolubilize the phosphatidylserine and separating the resultant insolubilized matter.
9. The method according to claim 8 , wherein said metallic salt is at least one metallic salt selected from the group comprising a lithium salt, a potassium salt, and a sodium salt.
10. The method according to claim 8 , wherein said metallic salt is lithium chloride, potassium chloride, or sodium chloride.
11. The method according to claim 8 , wherein the alcohol is ethyl alcohol.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/065,974 US20050170476A1 (en) | 2000-08-09 | 2005-02-24 | Method for producing phospholipid |
US11/654,192 US7695944B2 (en) | 2000-08-09 | 2007-01-17 | Method for producing phosholipid |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-241034 | 2000-08-09 | ||
JP2000241034A JP4298902B2 (en) | 2000-08-09 | 2000-08-09 | Method for producing phospholipids |
PCT/JP2001/006502 WO2002012532A1 (en) | 2000-08-09 | 2001-07-27 | Process for the production of phospholipids |
US10/344,063 US20030148477A1 (en) | 2000-08-09 | 2001-07-27 | Process for the production of phospholipids |
US11/065,974 US20050170476A1 (en) | 2000-08-09 | 2005-02-24 | Method for producing phospholipid |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/344,063 Continuation US20030148477A1 (en) | 2000-08-09 | 2001-07-27 | Process for the production of phospholipids |
US10344063 Continuation | 2001-07-27 | ||
PCT/JP2001/006502 Continuation WO2002012532A1 (en) | 2000-08-09 | 2001-07-27 | Process for the production of phospholipids |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/654,192 Continuation US7695944B2 (en) | 2000-08-09 | 2007-01-17 | Method for producing phosholipid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050170476A1 true US20050170476A1 (en) | 2005-08-04 |
Family
ID=18732297
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/344,063 Abandoned US20030148477A1 (en) | 2000-08-09 | 2001-07-27 | Process for the production of phospholipids |
US11/065,974 Abandoned US20050170476A1 (en) | 2000-08-09 | 2005-02-24 | Method for producing phospholipid |
US11/654,192 Expired - Fee Related US7695944B2 (en) | 2000-08-09 | 2007-01-17 | Method for producing phosholipid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/344,063 Abandoned US20030148477A1 (en) | 2000-08-09 | 2001-07-27 | Process for the production of phospholipids |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/654,192 Expired - Fee Related US7695944B2 (en) | 2000-08-09 | 2007-01-17 | Method for producing phosholipid |
Country Status (13)
Country | Link |
---|---|
US (3) | US20030148477A1 (en) |
EP (1) | EP1310563B1 (en) |
JP (1) | JP4298902B2 (en) |
KR (1) | KR100820657B1 (en) |
CN (1) | CN1318598C (en) |
AT (1) | ATE435298T1 (en) |
AU (1) | AU2002229150A1 (en) |
BR (1) | BR0113132B1 (en) |
CA (1) | CA2417597C (en) |
DE (1) | DE60139129D1 (en) |
ES (1) | ES2328014T3 (en) |
IL (2) | IL154218A0 (en) |
WO (1) | WO2002012532A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004107875A1 (en) * | 2003-06-06 | 2004-12-16 | Nagase Chemtex Corporation | Phospholipid-containing emulsifiable composition |
DE102004002053A1 (en) * | 2004-01-15 | 2005-08-04 | Bioghurt Biogarde Gmbh & Co. Kg | Process for the preparation of phosphatidylserine and its purification by extraction |
US20050158835A1 (en) * | 2004-01-21 | 2005-07-21 | Su Chen | Preparation of highly polyunsaturated fatty acid-containing phosphatidylserine and phosphatidic acid |
ITPD20050164A1 (en) | 2005-05-30 | 2006-11-30 | Fidia Farmaceutici | PROCESS FOR PREPARATION AND ISOLATION OF PHOSPHATIDES |
KR101122388B1 (en) * | 2009-05-23 | 2012-03-23 | 주식회사 고센바이오텍 | The method for biosynthesis of phosphatidylserine by chinese cabbage phospholipase D from egg yolk phospholipid |
KR101055094B1 (en) * | 2009-05-23 | 2011-08-08 | 주식회사 고센바이오텍 | Biosynthesis Method of Phosphatidylserine from Egg Yolk Phospholipids by Cabbage Phospholipase D |
CN103555783B (en) * | 2013-10-24 | 2015-08-12 | 陕西源邦生物技术有限公司 | A kind of method preparing phosphatidylserine |
CN104327114A (en) * | 2014-11-06 | 2015-02-04 | 江南大学 | Preparation method of phosphatidyl serine |
CN109628517A (en) * | 2018-12-27 | 2019-04-16 | 南通励成生物工程有限公司 | A kind of method that ultrasound-assisted enzymolysis prepares phosphatidylserine |
CN111534375B (en) * | 2020-05-26 | 2022-02-08 | 内蒙古铂贝曼科技有限公司 | Preparation method of aqueous phospholipid elastomer |
WO2022227248A1 (en) * | 2021-04-27 | 2022-11-03 | 内蒙古铂贝曼科技有限公司 | Active phospholipid layered liquid crystal, preparation process thereof and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733892A (en) * | 1990-07-24 | 1998-03-31 | Seikagaku Corporation | Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same |
US5900409A (en) * | 1994-11-08 | 1999-05-04 | Kabushiki Kaisha Yakult Honsha | Cerebration improver |
US6492146B1 (en) * | 1999-04-28 | 2002-12-10 | Chemi S.P.A. | Process for the preparation of phosphatidylserines |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0716426B2 (en) * | 1986-08-01 | 1995-03-01 | 日本油脂株式会社 | Method for producing phospholipid by enzyme |
JP2657274B2 (en) * | 1987-04-21 | 1997-09-24 | 株式会社ヤクルト本社 | Method for producing phospholipid |
JP2942302B2 (en) * | 1990-04-10 | 1999-08-30 | 株式会社ヤクルト本社 | Phosphatidyl ascorbate, production method thereof, emulsifier, lipid peroxide inhibitor and cosmetic |
JP2981294B2 (en) * | 1991-02-22 | 1999-11-22 | 花王株式会社 | Method for producing phosphatidic acid |
JP3791951B2 (en) * | 1995-11-08 | 2006-06-28 | 株式会社ヤクルト本社 | Method for producing oil and fat composition containing polyunsaturated fatty acid-containing phosphatidylserine |
JP3291289B2 (en) * | 2000-01-19 | 2002-06-10 | サンユレック株式会社 | Electronic component manufacturing method |
DE60017563T2 (en) * | 1999-06-15 | 2005-12-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | ENZYMATIC PREPARATION OF PHOSPHOLIPIDES IN AQUEOUS MEDIA |
-
2000
- 2000-08-09 JP JP2000241034A patent/JP4298902B2/en not_active Expired - Lifetime
-
2001
- 2001-07-27 BR BRPI0113132-0A patent/BR0113132B1/en not_active IP Right Cessation
- 2001-07-27 IL IL15421801A patent/IL154218A0/en unknown
- 2001-07-27 US US10/344,063 patent/US20030148477A1/en not_active Abandoned
- 2001-07-27 WO PCT/JP2001/006502 patent/WO2002012532A1/en active Application Filing
- 2001-07-27 AT AT01984491T patent/ATE435298T1/en active
- 2001-07-27 KR KR1020037001560A patent/KR100820657B1/en not_active IP Right Cessation
- 2001-07-27 EP EP01984491A patent/EP1310563B1/en not_active Expired - Lifetime
- 2001-07-27 DE DE60139129T patent/DE60139129D1/en not_active Expired - Lifetime
- 2001-07-27 CN CNB018170919A patent/CN1318598C/en not_active Expired - Fee Related
- 2001-07-27 AU AU2002229150A patent/AU2002229150A1/en not_active Abandoned
- 2001-07-27 ES ES01984491T patent/ES2328014T3/en not_active Expired - Lifetime
- 2001-07-27 CA CA002417597A patent/CA2417597C/en not_active Expired - Fee Related
-
2003
- 2003-01-30 IL IL154218A patent/IL154218A/en not_active IP Right Cessation
-
2005
- 2005-02-24 US US11/065,974 patent/US20050170476A1/en not_active Abandoned
-
2007
- 2007-01-17 US US11/654,192 patent/US7695944B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733892A (en) * | 1990-07-24 | 1998-03-31 | Seikagaku Corporation | Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same |
US5900409A (en) * | 1994-11-08 | 1999-05-04 | Kabushiki Kaisha Yakult Honsha | Cerebration improver |
US6492146B1 (en) * | 1999-04-28 | 2002-12-10 | Chemi S.P.A. | Process for the preparation of phosphatidylserines |
Also Published As
Publication number | Publication date |
---|---|
BR0113132A (en) | 2003-07-15 |
EP1310563B1 (en) | 2009-07-01 |
JP4298902B2 (en) | 2009-07-22 |
AU2002229150A1 (en) | 2002-02-18 |
CA2417597A1 (en) | 2003-01-28 |
IL154218A (en) | 2008-07-08 |
JP2002051794A (en) | 2002-02-19 |
WO2002012532A1 (en) | 2002-02-14 |
KR100820657B1 (en) | 2008-04-10 |
US20030148477A1 (en) | 2003-08-07 |
BR0113132B1 (en) | 2012-03-06 |
KR20030033014A (en) | 2003-04-26 |
CN1468314A (en) | 2004-01-14 |
EP1310563A1 (en) | 2003-05-14 |
US20070134776A1 (en) | 2007-06-14 |
US7695944B2 (en) | 2010-04-13 |
CA2417597C (en) | 2007-06-26 |
ATE435298T1 (en) | 2009-07-15 |
IL154218A0 (en) | 2003-07-31 |
DE60139129D1 (en) | 2009-08-13 |
ES2328014T3 (en) | 2009-11-06 |
CN1318598C (en) | 2007-05-30 |
EP1310563A4 (en) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7695944B2 (en) | Method for producing phosholipid | |
TWI378793B (en) | Producing method of phospholipids including long-chain polyunsaturated fatty acids as constituents, and use of such phospholipids | |
AU2004273700B2 (en) | Stabilized formulations of phosphatidylserine | |
RU2289625C2 (en) | Method for production of pure phosphides and uses thereof in cosmetic, pharmaceutics, and food | |
EP1740708B1 (en) | Enzymatic production of hydrolyzed lecithin products | |
AU2007205762B2 (en) | Process for the production of phospholipids | |
US5100787A (en) | Method for preparing highly purified phosphatidylinositol | |
US8637278B2 (en) | Method for the enzymatic production of emulsifiers containing mono- and diacylglycerides | |
JP2001186898A (en) | Method for producing phosphatidyl serine having polyvalent unsaturated fatty acid residue | |
JP5041790B2 (en) | Process for producing phosphatidylserine having polyunsaturated fatty acid as a constituent | |
KR100225669B1 (en) | Process for preparing highly pure phospholipid using enzyme | |
JP2683590B2 (en) | Method for producing enzyme-converted phospholipid | |
JPH0216989A (en) | Production of omega6-based unsaturated fatty acid-containing phospholipid | |
JPH0253726A (en) | Agent for lowering cholesterol and novel phospholipid | |
PL239133B1 (en) | Method of enzymatic enrichment of lecithin in a conjugated linoleic acid isomer | |
PL239132B1 (en) | Method of enzymatic enrichment of lecithin in a conjugated linoleic acid isomer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KABUSHIKI KAISHA YAKULT HONSHA, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAKAI, MASASHI;EBINA, RIKA;YAMATOYA, HIDEYUKI;AND OTHERS;REEL/FRAME:016337/0958;SIGNING DATES FROM 20030115 TO 20030130 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |